{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:22:12Z","timestamp":1794644532631,"version":"4.9.1"},"reference-count":20,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Achieve Life Sciences","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Quitting smoking is essential for stabilising and improving respiratory function in people with chronic obstructive pulmonary disease (COPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of cytisinicline versus placebo for cessation among smokers with and without COPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis used combined data from the phase 3 ORCA-2 (Ongoing Research of Cytisinicline for Addiction) and ORCA-3 double-blind, placebo-controlled trials. Participants received 6 or 12 weeks of cytisinicline or placebo. Of 1602 participants, 145 (9.3%) self-reported COPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants received 3\u2009mg of cytisinicline three times daily (6 weeks: n=532; 12 weeks: n=534) or placebo (12 weeks: n=536), plus behavioural support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome<\/jats:title>\n                    <jats:p>Biochemically verified continuous smoking abstinence during the last 4 treatment weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>COPD participants were older, smoked longer and had greater nicotine dependence. Cytisinicline was associated with significantly higher smoking abstinence compared with placebo in both COPD and non-COPD subgroups. There was no statistical evidence of heterogeneity in treatment effect between arms. In the 6-week arm, quit estimates were 17.3% versus 2.1% (OR 9.7, p=0.03) for COPD and 19.3% versus 5.5% (OR 4.1, p&lt;0.0001) for non-COPD. In the 12-week arm, quit estimates were 19.1% versus 4.3% (OR 5.3, p=0.04) for COPD and 32.6% versus 8.6% (OR 5.2, p&lt;0.0001) for non-COPD. Cytisinicline was well tolerated with no serious treatment-related events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cytisinicline significantly increased quitting for smokers with and without COPD and was well tolerated. The findings support cytisinicline as a viable treatment for smokers with COPD who want to quit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      ORCA-2 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04576949\">NCT04576949<\/jats:ext-link>\n                      ) and ORCA-3 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05206370\">NCT05206370<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223880","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:20:40Z","timestamp":1758129640000},"page":"164-169","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials"],"prefix":"10.1136","volume":"81","clinical-trial-number":[{"clinical-trial-number":"nct04576949","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05206370","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04576949","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7925-326X","authenticated-orcid":false,"given":"Judith","family":"Prochaska","sequence":"first","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3682-442X","authenticated-orcid":false,"given":"Mark","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Achieve Life Sciences Inc, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Perdok","sequence":"additional","affiliation":[{"name":"Achieve Life Sciences Inc, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Blumenstein","sequence":"additional","affiliation":[{"name":"Trial Architecture Consulting, Port Saint Lucie, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4757-6344","authenticated-orcid":false,"given":"Cindy","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Achieve Life Sciences Inc, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"2026012006550569000_81.2.164.1","unstructured":"U.S. Department of Health and Human Services . The health consequences of smoking\u201450 years of progress: a report of the surgeon general. Atlanta, GA U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014."},{"key":"2026012006550569000_81.2.164.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00056-X"},{"key":"2026012006550569000_81.2.164.3","first-page":"289","article-title":"Employment and activity limitations among adults with chronic obstructive pulmonary disease--United States, 2013","volume":"64","author":"Wheaton","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026012006550569000_81.2.164.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00160007"},{"key":"2026012006550569000_81.2.164.5","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.9901044"},{"key":"2026012006550569000_81.2.164.6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1042\/CS20160093","article-title":"Influenza A virus infection and cigarette smoke impair bronchodilator responsiveness to \u03b2-adrenoceptor agonists in mouse lung","volume":"130","author":"Donovan","year":"2016","journal-title":"Clin Sci"},{"key":"2026012006550569000_81.2.164.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2021.09.006"},{"key":"2026012006550569000_81.2.164.8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.amepre.2021.12.001","article-title":"Smoking Cessation Among U.S. Adult Smokers With and Without Chronic Obstructive Pulmonary Disease, 2018","volume":"62","author":"Liu","year":"2022","journal-title":"Am J Prev Med"},{"key":"2026012006550569000_81.2.164.9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000523973","article-title":"Mental Health Symptoms and Associations with Tobacco Smoking, Dependence, Motivation, and Attempts to Quit: Findings from a Population Survey in Germany (DEBRA Study)","volume":"28","author":"Kastaun","year":"2022","journal-title":"Eur Addict Res"},{"key":"2026012006550569000_81.2.164.10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1192\/bja.2020.52","article-title":"Addressing concerns about smoking cessation and mental health: theoretical review and practical guide for healthcare professionals","volume":"27","author":"Taylor","year":"2021","journal-title":"BJPsych advances"},{"key":"2026012006550569000_81.2.164.11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.5.1365"},{"key":"2026012006550569000_81.2.164.12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/1574886311207040282","article-title":"Adverse Effects Cause Varenicline Discontinuation: A Meta-Analysis","volume":"11","author":"Drovandi","year":"2016","journal-title":"CDS"},{"key":"2026012006550569000_81.2.164.13","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntr003"},{"key":"2026012006550569000_81.2.164.14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jama.2023.10042","article-title":"Cytisinicline for Smoking Cessation: A Randomized Clinical Trial","volume":"330","author":"Rigotti","year":"2023","journal-title":"JAMA"},{"key":"2026012006550569000_81.2.164.15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/jamainternmed.2025.0628","article-title":"Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial","volume":"185","author":"Rigotti","year":"2025","journal-title":"JAMA Intern Med"},{"key":"2026012006550569000_81.2.164.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00995.x"},{"key":"2026012006550569000_81.2.164.17","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.064410"},{"key":"2026012006550569000_81.2.164.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092614"},{"key":"2026012006550569000_81.2.164.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0865"},{"key":"2026012006550569000_81.2.164.20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1183\/20734735.0346-2018","article-title":"Under- and over-diagnosis of COPD: a global perspective","volume":"15","author":"Ho","year":"2019","journal-title":"Breathe (Sheff)"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:55:28Z","timestamp":1768920928000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,15]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/thorax-2025-223880"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223880","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}